Atrosulf review

Atrosulf is a tropane alkaloid obtained from Atropa belladonna (deadly nightshade), Datura stramonium (jimsonweed), Mandragora officinarum (mandrake), and other plants of the family Solanaceae. This versatile medicament is a secondary metabolite of the above plants and provides a variety of effects and uses. Classified as an anticholinergic medicament, it serves as a competitive antagonist for the muscarinic acetylcholine receptor.

Due to Atrosulf's potential deadliness, the medicament derives its name from one of the three Fates, Atropos, who, according to Greek mythology, chose how a person would die. The World Health Organization considers this a core medicine for the association's Essential Drugs List. This is a list of minimum medical requirements for a basic healthcare system.

Adult doses range from around half a milligram to one milligram or five to ten milliliters of the 0.1 milligram/milliliter solution for antisialagogue and other antivagal effects, plus two to three milligrams or twenty to thirty milliliters of the 0.1 milligram/milliliter solution as an antidote for organophosporous muscarinic mushroom poisoning.

Patients without access to an IV should use the endotracheal administration of Atrosulf. The recommended adult dose of Atrosulf for endotracheal administration is one to two milligrams diluted to a total of no more than ten milliliters of normal saline or sterile water. For cases that are not serious or critical, titration intervals of one or two hours are most suitable.

Atrosulf Sulfate Injection (USP) should be administered with care when given to all individuals over forty years of age. Acute glaucoma in susceptible patients may occur during Atrosulf treatment. Conventional systemic doses may lead to complete urinary retention in patients with prostatic hypertrophy, convert partial organic pyloric stenosis into complete obstruction, or cause inspissation of bronchial secretions and formation of dangerous viscid plugs in patients with chronic lung disease. Inform your doctor of your complete medical history before starting treatment. This is of the utmost importance.

Even though the recurrent use of Atrosulf is crucial in patients suffering from coronary artery disease, the total dose of the medicine should not exceed two to three (maximum 0.03 to 0.04 milligrams/kilograms) to prevent the harmful side effects of Atrosulf-caused tachycardia on myocardial oxygen demand.

As for patients suffering from bradyasystolic cardiopulmonary arrest, a single milligram dose of Atrosulf should be taken intravenously and repeated every three to five minutes until symptoms subside. Three milligrams (0.04 milligrams/kilograms) given intravenously is a completely vagolytic dose in most patients. Also, the administration of less than 0.05 milligrams can produce a paradoxical bradycardia because of the peripheral or central parasympathomimatic effects of low dose Atrosulf in some adults.

Atrosulf's two to three milligram dose should be repeated no less than every twenty to thirty minutes when being used as an antidote until symptoms are significantly reduced or until signs of Atrosulf poisoning occur. For most patients, the initial dose is usually around 0.01 to 0.03 milligrams/kilograms of body weight. Dosing information for children hasn't been well researched. Therefore consult your doctor before considering this medicament for a child.

Side effects include tachycardia, photophobia, blurred vision, and dryness of mouth. These symptoms commonly occur with chronic administration of therapeutic doses. Anhidrosis, heat intolerance, and impaired temperature regulation may also occur in patients living in an arid environment. Elderly patients may suffer urination difficulties and constipation. Occasional hypersensitivity, skin rashes, and exfoliation have also been reported. If you experience any of these symptoms, consult your doctor.

Side effects due to excessive dose (Atrosulf poisoning) include ataxia, fatigue, tremor, restlessness, dizziness, thirst, hot and dry skin, difficulty swallowing, dilated pupils, and abnormality of heartbeat. In some cases, it may lead to coma, delirium, hallucinations, restlessness and excitement, and marked abnormality of heartbeat. Severe intoxication while undergoing Atrosulf treatment can lead to circulatory collapse and depression. Patients need to stay away from alcohol consumption while taking this medicament. Consult your doctor immediately if you experience any of these symptoms.

Atrosulf has the following structural formula:

Chemical structure of atrosulf

• Molecular formula of atrosulf is C17H23NO3
• Chemical IUPAC Name is (8-methyl-8-azabicyclo[3.2.1]oct-3-yl) 3-hydroxy-2-phenyl-propanoate
• Molecular weight is 289.369 g/mol
Atrosulf available : 5ml 1% bottles

Generic name: Atropine

Brand name(s): Atnaa, Atropair, Atropen, Atropin, Atropina, Atropinol, Atropisol, Equipin, Eyesules, Hyoscyamine, I-Tropine, Isopto atropine, Minims atropine, Ocu-Tropine, Tropine tropate, Troyl tropate

  Your Atrosulf review